Skip to main content

Table 1 Clinical trials of EpCAM, HER family, CEA- and PSMA-related BsAbs in solid tumors

From: Recent advances of bispecific antibodies in solid tumors

BsAb Targets Format Function Diseases Phase Stage Identifier
Catumaxomab EpCAM/CD3 Triomab Redirect T cells and accessory cells Ovarian cancer II Completed NCT00189345
Catumaxomab EpCAM/CD3 Triomab Redirect T cells and accessory cells EpCAM positive tumor, malignant ascites II/III Completed NCT00836654
Catumaxomab EpCAM/CD3 Triomab Redirect T cells and accessory cells Gastric cancer, adenocarcinoma II Completed NCT00464893
Catumaxomab EpCAM/CD3 Triomab Redirect T cells and accessory cells Gastric adenocarcinomas II Active, not recruiting NCT01504256
Catumaxomab EpCAM/CD3 Triomab Redirect T cells and accessory cells Ovarian cancer II Completed NCT01246440
Catumaxomab EpCAM/CD3 Triomab Redirect T cells and accessory cells Gastric peritoneal carcinomatosis II Terminated NCT01784900
Catumaxomab EpCAM/CD3 Triomab Redirect T cells and accessory cells Epithelial cancer I Terminated NCT01320020
Catumaxomab EpCAM/CD3 Triomab Redirect T cells and accessory cells Malignant ascites III Completed NCT00822809
MT110 EpCAM/CD3 BiTE T cell recruitment EpCAM-positive solid tumors I Completed NCT00635596
Ertumaxomab HER2/CD3 Triomab Redirect T cells and accessory cells Breast cancer II Terminated NCT00452140
Ertumaxomab HER2/CD3 Triomab Redirect T cells and accessory cells Breast cancer II Terminated NCT00522457
Ertumaxomab HER2/CD3 Triomab Redirect T cells and accessory cells Her2 positive advanced solid tumors I/II Terminated NCT01569412
HER2Bi-aATC HER2/CD3 T cells armed with BsAbs Activated T cells Her2-positive neoplasms I Recruiting NCT02662348
EGFRBi-aATC EGFR/CD3 T cells armed with BsAbs Activated T cells Advanced solid tumors I Terminated NCT01081808
MDX-447 EGFR/CD64 2(Fab’) Active monocytes Brain and central nervous system tumors I Completed NCT00005813
MM-111 HER2/HER3 HSA body Blockade of 2 receptors HER2 amplified solid tumors I Completed NCT00911898
MM-111 + Herceptin HER2/HER3 HSA body Blockade of 2 receptors Breast cancer I Completed NCT01097460
MCLA-128 HER2/HER3 Full Length IgG1 Blockade of 2 receptors Malignant solid tumors I/II Recruiting NCT02912949
MM-141 HER3/IGF-IR scFv-IgG Blockade of 2 receptors Hepatocellular carcinoma I Completed NCT01733004
MM-141 HER3/IGF-IR scFv-IgG Blockade of 2 receptors Pancreatic cancer II Recruiting NCT02399137
LY3164530 EGFR/MET OrthoFab-IgG Blockade of 2 receptors Advanced or metastatic cancer I Active, not recruiting NCT02221882
TargomiRs EGFR/EDV Unclear Delivery of nanoparticles MPM and NSCLC I Recruiting NCT02369198
EGFR(V)-EDV-Dox EGFR/EDV Unclear Delivery of nanoparticles Glioblastoma I Recruiting NCT02766699
AMG211 CEA/CD3 BiTE T cell recruitment Gastrointestinal cancer I Recruiting NCT02760199
AMG211 CEA/CD3 BiTE T cell recruitment Gastrointestinal cancer I Recruiting NCT02291614
AMG211 CEA/CD3 BiTE T cell recruitment Gastrointestinal adenocarcinomas I Recruiting NCT01284231
RO6958688 CEA/CD3 IgG-based T cell recruitment CEA-positive solid tumors I Recruiting NCT02324257
RO6958688+Atezolizumab CEA/CD3 IgG-based T cell recruitment CEA-positive solid tumors I Recruiting NCT02650713
RO6895882 CEA/IL2 ScFv-IgG The delivery of cytokines CEA-positive solid tumors I Completed NCT02004106
TF2 CEA/HSG Dock and lock Radioimmunotherapy Colorectal cancer I Completed NCT00860860
TF2 CEA/ HSG Dock and lock Radioimmunotherapy Small cell lung cancer I/II Completed NCT01221675
TF2 CEA/ HSG Dock and lock Immuno-PET Medullary thyroid carcinoma I/II Completed NCT01730638
TF2 CEA/ HSG Dock and lock Immuno-PET Breast carcinoma expressing CEA I/II Ongoing NCT01730612
TF2 CEA/ HSG Dock and lock Radioimmunotherapy Colorectal cancer I Terminated NCT01273402
TF2 CEA/ HSG Dock and lock Immuno-PET Colorectal cancer II Completed NCT02587247
Anti-CEAxanti-DTPA CEA/di-DTPA-131 scFv-IgG Radioimmunotherapy Medullary thyroid carcinoma II Completed NCT00467506
BAY2010112 PSMA/CD3 BiTE T cell recruitment CRPC I ongoing NCT01723475
MOR209/ES414 PSMA/CD3 ScFv-Fc-scFv T cell recruitment mCRPC I Recruiting NCT02262910
  1. The details of Table 1 derived from http://clinicaltrials.gov/